Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Thermo Fisher Scientific to Acquire Life Technologies Corporation

Published: Monday, April 15, 2013
Last Updated: Monday, April 15, 2013
Bookmark and Share
The definitive agreement will see Thermo Fisher will acquire Life Technologies for $76.00 in cash per fully diluted common share or approximately $13.6 billion.

The transaction, which was approved by both companies’ boards of directors, will create an unrivaled leader in serving research, specialty diagnostics and applied markets. The combination builds on both companies’ technological strengths to accelerate results for life sciences customers working in proteomics, genomics and cell biology.

“We are extremely excited about this transaction because it creates the ultimate partner for our customers and significant value for our shareholders,” said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. “The acquisition of Life Technologies enhances all three elements of our growth strategy: technological innovation, a unique customer value proposition and expansion in emerging markets.

“Our customers in research and applied markets will now be able to achieve even higher levels of innovation and productivity by working with the combined company. We’re especially excited about the new opportunities we will have to leverage our complementary offerings, fueled by a shared commitment to continuous innovation. For our shareholders, we expect the transaction to generate attractive financial returns, as well as significant and immediate accretion to our adjusted EPS.”

Gregory T. Lucier, chairman and chief executive officer of Life Technologies, said, “This transaction brings together two companies intent on accelerating innovation for our customers and achieving greater success in a highly competitive global industry. Further, this combination delivers immediate and significant cash value to our stockholders and represents a successful conclusion to the board’s strategic review to enhance stockholder value and develop an even stronger future for Life Technologies. We look forward to joining forces with the outstanding team at Thermo Fisher, which shares our commitment to customers, employees and the communities we serve.”

Casper added, “We look forward to welcoming our new colleagues from Life Technologies to the Thermo Fisher team. Together, we will be in an even stronger position to fulfill our company’s mission, which is to enable our customers to make the world healthier, cleaner and safer.”

Life provides innovative products and services to customers conducting scientific research and genetic analysis, as well as those in applied markets, such as forensics and food safety testing. With 2012 revenues of $3.8 billion, its comprehensive offering includes a broad range of reagents, consumables, instruments and systems. Life’s leading technologies are protected by approximately 5,000 patents and licenses, and it builds on this position through a strong commitment to innovation. Life has an expansive commercial presence and global footprint as well, with more than 10,000 employees serving its customers around the world. 

It is expected that Life Technologies’ president and chief operating officer, Mark P. Stevenson, will have a significant leadership role in the combined company. In addition, Thermo Fisher intends to elect a member of the Life Technologies board of directors to the Thermo Fisher board.

Benefits of the Transaction 
The acquisition of Life Technologies will create enhanced scale and depth of capabilities for customers working in research, specialty diagnostics and applied markets.

• Strengthens technology and innovation leadership through complementary offerings that broaden Thermo Fisher’s industry-leading portfolio. Life has an extensive offering of consumables for genomics, and molecular and cell biology. It is well-known for its next-generation sequencing capability, and also has a range of technologies for bioproduction and forensics applications. These strengths, combined with Thermo Fisher’s leading offerings in analytical technologies and specialty diagnostics, create new opportunities to support the convergence of life sciences tools and diagnostics.
• Creates the ultimate customer partner, enhancing Thermo Fisher’s commercial strength and global reach. Life transacts more than half of its orders online through a highly regarded e-commerce platform. This leading capability, combined with Thermo Fisher’s extensive research and healthcare customer channels, creates a world-class commercial infrastructure. The combined company will also build on its strong foothold in Asia-Pacific, particularly in China, to meet increasing customer demand in life sciences and healthcare.
• Creates compelling value for shareholders, with attractive financial returns and new growth opportunities. The acquisition of Life presents the opportunity for $275 million of adjusted operating income synergies in year three following the close, consisting of $250 million of cost synergies and $25 million of revenue synergies. In addition, Thermo Fisher expects the transaction to be significantly and immediately accretive to adjusted EPS.

Financing and Approvals
Thermo Fisher will acquire Life for $76.00 in cash per fully diluted common share. The transaction, which is expected to close early in 2014, is subject to a Life shareholder vote and satisfying customary closing conditions, including regulatory approvals. Thermo Fisher has obtained committed bridge financing from J.P. Morgan and Barclays. Of the $13.6 billion of total cash consideration, the company expects the split to be cash and debt of $9.5 to $10.0 billion and equity of up to $4.0 billion. Thermo Fisher expects to maintain an investment-grade rating after the transaction has closed.

Advisors
J.P. Morgan and Barclays are acting as financial advisors to Thermo Fisher, and Wachtell, Lipton, Rosen & Katz and WilmerHale are serving as legal counsel. For Life, Deutsche Bank Securities Inc. and Moelis & Company are serving as financial advisors, and Cravath, Swaine and Moore LLP is serving as legal counsel.

Use of Non-GAAP Financial Measures 
In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures, including adjusted EPS and adjusted operating income, which exclude restructuring and other costs/income and amortization of acquisition-related intangible assets. Adjusted EPS also excludes certain other gains and losses, tax provisions/benefits related to the previous items, benefits from tax credit carryforwards, the impact of significant tax audits or events and discontinued operations. We exclude the above items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods. We believe that the use of non-GAAP measures helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the company's performance, especially when comparing such results to previous periods or forecasts. 


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Thermo to Acquire FEI Company
Leading electron microscopy platform complements mass spectrometry leadership to accelerate advancements in structural biology.
Tuesday, May 31, 2016
Advancing Lithium-Ion Battery Research
The increasing number of components in a lithium-ion battery makes it essential to use a variety of analytical methods to attain complete characterization.
Wednesday, October 28, 2015
Automating Deep Characterization of Biotherapeutic Proteins
Thermo's new PepFinder software streamlines relative and absolute quantitation, and identification of proteins from biological samples using LC-MS.
Thursday, June 19, 2014
Thermo Scientific Chromatography Columns/Consumables Catalog Goes Mobile
2014-15 Chromatography Columns and Consumables Catalog now available in print, pdf and interactive mobile versions.
Thursday, February 27, 2014
Thermo Collaborates with Leading EU and UK Pesticide Testing Labs
The company's Pesticide Analysis Center of Excellence provides technology, consultation and support.
Tuesday, November 19, 2013
Thermo Scientific at ASMS 2013
Learn how scientists and researchers are transforming science by applying innovative solutions to a wide range of qualitative and quantitative applications.
Monday, May 13, 2013
Thermo Fisher Scientific Reports First Quarter 2013 Results
Adjusted earnings per share grew 17% to a record $1.37 with revenue increased 4% to a first quarter record of $3.19 billion.
Thursday, April 25, 2013
Thermo Fisher Scientific to Acquire Life Technologies
Transaction expected to create an unrivaled leader in serving research, specialty diagnostics and applied markets.
Wednesday, April 17, 2013
Thermo Fisher Scientific Facilities Achieve ISO 13485 Certification
The facilities in San Jose, CA and Franklin, MA have achieved the internationally recognized standard of quality management for the design and manufacture of medical devices.
Thursday, April 04, 2013
Thermo Fisher Scientific to Acquire picoSpin
Thermo Fisher Scientific Inc. has completed a purchase of picoSpin, LLC, creators of the world’s first miniature NMR spectrometer.
Friday, December 21, 2012
Hyperion Succesfully Completes Laboratory Infrastructure Project for Hellenic Petroleum
Hyperion and the Hellenic Petroleum Group have completed a major upgrade and extension project for the LIMS at three Greek petroleum refineries of the Group.
Wednesday, November 21, 2012
Thermo Fisher Scientific Reports Q3 Revenue and EPS Results
Revenue increased 5% to a record $3.09 billion for the third quarter with adjusted operating income rising 5% to $576 million.
Wednesday, October 24, 2012
Thermo Fisher Scientific and Immundiagnostik Collaborate
The collaboration aims to develop novel mass spectrometry-based assays for qualitative and quantitative analysis of proteins and peptides.
Wednesday, October 17, 2012
Thermo Fisher Scientific and bioMérieux Renew Partnership
The companies have renewed their non-exclusive, long-term, royalty-bearing agreement for Procalcitonin testing.
Wednesday, October 03, 2012
Seminars on Advanced Solutions for Nutraceutical Analysis
Seminar sessions will discuss Company’s chromatography and elemental analysis techniques to optimize nutraceutical processes.
Tuesday, September 25, 2012
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Core-Shell Columns in HPLC: Food Analysis Applications
Explore the most recent applications of core-shell columns in food analysis.
Review of the Analysis of Haemoglobin A1c for Diabetes Diagnostics
This paper aims to clarify methods, units, quality requirements, reference and cutoff limits for hemoglobin A1c (HbA1c) and ratio of blood glucose/HbA1c on the basis of the results from Finnish quality control surveys by comparing them to the literature.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Connectome Map More Than Doubles Human Cortex’s Known Regions
Researchers at NIH have developed software that automatically detects the “fingerprint” of each of these areas in an individual’s brain scans.
Discovered Through ‘Big Data’ Analysis
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
Human Stem Cells to Rapidly Generate Bone, Heart Muscle
A new study shows that combining positive and negative signals can quickly and efficiently steer stem cells down complex developmental pathways to become specialized tissues that could be used in the clinic.
New Mechanism of Tuberculosis Infection
Researchers at UTSW Medical Center have identified a new way that tuberculosis bacteria get into the body, revealing a potential therapeutic angle to explore.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer and that, when deleted in the lungs of mice, prevents the cancer from forming.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!